← Back to Search

Virus Therapy

Booster Dose of BNT162b2 Vaccine for Cancer

Phase 2
Research Sponsored by Montefiore Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Above the age of 18
Underwent an in-person encounter at a study facility during the study period
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks after booster dose
Awards & highlights

Study Summary

This trial will test if a booster shot of the COVID vaccine is safe and effective in cancer patients who didn't develop antibodies from the original vaccine series.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks after booster dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks after booster dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rates of seroconversion for SARS-CoV-2 spike antibody

Trial Design

1Treatment groups
Experimental Treatment
Group I: Booster doseExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Montefiore Medical CenterLead Sponsor
440 Previous Clinical Trials
581,361 Total Patients Enrolled
Albert Einstein College of MedicineOTHER
285 Previous Clinical Trials
11,856,269 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the BNT162b2 vaccine been officially sanctioned by the FDA?

"BNT162b2 vaccine has been assessed to be a 2 on the rating scale. This is because, while there are some safety data available from Phase 2 trials, efficacy data remain unavailable at this time."

Answered by AI

Does this particular experiment offer a pioneering approach?

"Currently, 27 clinical trials testing BNT162b2 vaccine are occurring in 220 cities across 27 nations. This journey began with BioNTech SE's Phase 1 & 2 trial which included 512 participants and was completed in 2020. Since then, 16 investigations into the drug have been finished successfully."

Answered by AI

What other research has been undertaken with regard to the BNT162b2 immunization?

"Presently, there are 27 ongoing investigations into the efficacy of BNT162b2 vaccine with 6 in Phase 3. Primarily based in Roskilde and Aarhus N, these studies have expanded to 762 locations worldwide."

Answered by AI

Are applicants currently being accepted for this investigation?

"Updated information on clinicaltrials.gov confirms that this research study is enrolling patients now. This trial was first introduced to the public on August 10th 2021, and subsequently revised October 12th 2022."

Answered by AI

What is the highest patient capacity for this experiment?

"Indeed, the clinicaltrials.gov listing confirms that this trial is presently onboarding patients. This research study was first made available on August 10th 2021 and has since been refreshed on October 12th 2022. The investigators are seeking out 100 individuals at a single site to complete the experiment."

Answered by AI
~68 spots leftby Apr 2025